{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:36:55Z","timestamp":1787027815340,"version":"build-2736575974"},"reference-count":34,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T00:00:00Z","timestamp":1748563200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Hungarian National Research, Development and Innovation Office (NKFIH)","award":["K143021"],"award-info":[{"award-number":["K143021"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Neuroblastoma (NB) is one of the most common solid tumors in children, still showing a high mortality rate despite recent advances in therapy. A recent breakthrough was the introduction of Dinutuximab beta, yielding further improvements in survival. Dinutuximab beta is an anti-GD2 monoclonal antibody that targets GD2 expressed on the cell surface of neuroblastoma cells. Evidence suggests that Dinutuximab beta combined with Nivolumab may offer an effective synergistic treatment approach. Methods: In our center, immunotherapy was introduced in 2021 as part of maintenance treatment. The aim of this retrospective study was to analyze our data with a focus on the response, side effect profile and tolerability of Dinutuximab beta in HR and relapsed or refractory (r\/r) NB. Results: Between 2021 and 2024, we treated 15 patients with neuroblastoma. Twelve patients had high-risk disease, of whom five received Dinutuximab beta as part of maintenance treatment according to protocol HR-NBL 1.8\/SIOPEN. Two patients achieved complete remission after immunotherapy. One achieved long-lasting remission, while another relapsed. Three patients with inoperable tumors developed a partial response, but they relapsed and were diagnosed with metastases later. These patients subsequently initiated treatment with Temozolomide + Irinotecan in combination with Dinutuximab beta and also with Nivolumab as a relapse protocol. Therapeutic responses were assessed by the imaging, pathology and flow cytometry analysis of bone marrow. Apart from one complication (hypotension as part of capillary leak syndrome) subsiding spontaneously, no other severe adverse events were observed. Conclusions: Our experiences confirm that immunotherapy, including Dinutuximab beta and Nivolumab, is safe and well tolerated. The standardization of the application of Dinutuximab beta and in combination with novel therapeutic agents in maintenance and refractory\/relapsed cases may contribute to improved treatment outcome results.<\/jats:p>","DOI":"10.3390\/cancers17111824","type":"journal-article","created":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T06:14:27Z","timestamp":1748585667000},"page":"1824","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Single-Center Cohort of Pediatric Patients with High-Risk Neuroblastoma Receiving Immunotherapy"],"prefix":"10.3390","volume":"17","author":[{"given":"Emese","family":"Zsigrai","sequence":"first","affiliation":[{"name":"Division of Pediatric Hematology-Oncology, Department of Pediatrics, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0608-7704","authenticated-orcid":false,"given":"S\u00e1ndor","family":"Barna","sequence":"additional","affiliation":[{"name":"Nuclear Medicine, Medical Imaging Clinic, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-1097-3494","authenticated-orcid":false,"given":"Zsuzsanna","family":"Ga\u00e1l","sequence":"additional","affiliation":[{"name":"Division of Pediatric Hematology-Oncology, Department of Pediatrics, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8837-1322","authenticated-orcid":false,"given":"Lilla","family":"Macsi","sequence":"additional","affiliation":[{"name":"Division of Pediatric Hematology-Oncology, Department of Pediatrics, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Istv\u00e1n","family":"Szegedi","sequence":"additional","affiliation":[{"name":"Division of Pediatric Hematology-Oncology, Department of Pediatrics, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikl\u00f3s","family":"Petr\u00e1s","sequence":"additional","affiliation":[{"name":"Division of Pediatric Hematology-Oncology, Department of Pediatrics, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5170-5965","authenticated-orcid":false,"given":"Csongor","family":"Kiss","sequence":"additional","affiliation":[{"name":"Division of Pediatric Hematology-Oncology, Department of Pediatrics, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,5,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e30732","DOI":"10.1002\/pbc.30732","article-title":"A comprehensive analysis of neuroblastoma incidence, survival, and racial and ethnic disparities from 2001 to 2019","volume":"71","author":"Campbell","year":"2024","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1016\/j.ejca.2005.12.029","article-title":"Neuroblastoma in hungary","volume":"42","author":"Parker","year":"2006","journal-title":"Eur. J. Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"3229","DOI":"10.1200\/JCO.21.00278","article-title":"Revised Neuroblastoma Risk Classification System","volume":"39","author":"Irwin","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.1200\/JCO.19.00919","article-title":"Maintaining outstanding outcomes using response- and biology-based therapy for intermediate-risk neuroblastoma: A report from the Children\u2019s Oncology Group study ANBL0531","volume":"37","author":"Twist","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/s41571-022-00643-z","article-title":"Advancing therapy for neuroblastoma","volume":"19","author":"Qiu","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1200\/JCO.1993.11.8.1466","article-title":"Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment","volume":"11","author":"Brodeur","year":"1993","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/S0360-3016(99)00399-5","article-title":"Local control with multimodality therapy for stage 4 neuroblastoma","volume":"46","author":"Wolden","year":"2000","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S0360-3016(02)04506-6","article-title":"Impact of radiotherapy for high-risk neuroblastoma: A Children\u2019s Cancer Group study","volume":"56","author":"Swift","year":"2003","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"563","DOI":"10.2146\/ajhp160228","article-title":"Dinutuximab for maintenance therapy in pediatric neuroblastoma","volume":"74","author":"McGinty","year":"2017","journal-title":"Am. J. Health Syst. Pharm."},{"key":"ref_10","unstructured":"(2025, May 25). High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN) (HR-NBL2) ClinicalTrials.gov ID NCT04221035, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04221035."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1056\/NEJMoa2210859","article-title":"GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma","volume":"388","author":"Caruana","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_12","unstructured":"Gray, J. (2025, May 25). A Phase I Study of 131-1 mIBG Followed by Nivolumab and Dinutuximab Beta Antibody in Children with Relapsed\/Refractory Neuroblastoma. (The MINIVAN Trial). Available online: https:\/\/www.siopen.org\/siopen-clinical-trials-1\/a-phase-i-study-of-131-1-mibg-followed-by-nivolumab-and-dinutuximab-beta-antibody-in-children-with-relapsed\/refractory-neuroblastoma-the-minivan-trial."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e000540","DOI":"10.1136\/jitc-2020-000540","article-title":"Nivolumab and dinutuximab beta in two patients with refractory neuroblastoma","volume":"8","author":"Ehlert","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Siebert, N., Zumpe, M., Schwencke, C.H., Biskupski, S., Troschke-Meurer, S., Leopold, J., Zikoridse, A., and Lode, H.N. (2023). Combined Blockade of TIGIT and PD-L1 Enhances Anti-Neuroblastoma Efficacy of GD2-Directed Immunotherapy with Dinutuximab Beta. Cancers, 15.","DOI":"10.3390\/cancers15133317"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"5088","DOI":"10.1158\/1078-0432.CCR-22-2164","article-title":"A Phase I\/II Trial of Nivolumab plus Ipilimumab in Children and Young Adults with Relapsed\/Refractory Solid Tumors: A Children\u2019s Oncology Group Study ADVL1412","volume":"28","author":"Davis","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1007\/s40265-015-0399-5","article-title":"Dinutuximab: First global approval","volume":"75","author":"Dhillon","year":"2015","journal-title":"Drugs"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1056\/NEJMoa0911123","article-title":"Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma","volume":"363","author":"Yu","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Ladenstein, R., P\u00f6tschger, U., Valteau-Couanet, D., Luksch, R., Castel, V., Ash, S., Laureys, G., Brock, P., Michon, J.M., and Owens, C. (2020). Investigation of the Role of Dinutuximab Beta-Based Immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 Trial (HR-NBL1). Cancers, 12.","DOI":"10.3390\/cancers12020309"},{"key":"ref_19","first-page":"1","article-title":"Spotlight on dinutuximab in the treatment of high-risk neuroblastoma: Development and place in therapy","volume":"13","author":"Keyel","year":"2019","journal-title":"Biologics"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1179559X17719106","DOI":"10.1177\/1179559X17719106","article-title":"Dinutuximab in the treatment of high risk neuroblastoma in children","volume":"9","author":"Gur","year":"2017","journal-title":"Clin. Med. Insights Ther."},{"key":"ref_21","first-page":"71","article-title":"Safety and efficacy of dinutuximab in the treatment of neuroblastoma: A review","volume":"28","author":"Mohd","year":"2023","journal-title":"J. Res. Med. Sci."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Wieczorek, A., \u017bebrowska, U., Ussowicz, M., Sok\u00f3\u0142, A., Stypi\u0144ska, M., Dembowska-Bagi\u0144ska, B., Pawi\u0144ska-W\u0105sikowska, K., and Balwierz, W. (2023). Dinutuximab Beta Maintenance Therapy in Patients with High-Risk Neuroblastoma in First-Line and Refractory\/Relapsed Settings-Real-World Data. J. Clin. Med., 12.","DOI":"10.3390\/jcm12165252"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Wieczorek, A., Zaniewska-Tekieli, A., Ehlert, K., Pawinska-Wasikowska, K., Balwierz, W., and Lode, H. (2023). Dinutuximab beta combined with chemotherapy in patients with relapsed or refractory neuroblastoma. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1082771"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Hoshi, Y., Enokida, T., Tamura, S., Nakashima, T., Okano, S., Fujisawa, T., Sato, M., Wada, A., Tanaka, H., and Takeshita, N. (2024). Efficacy of anti-PD-1 monotherapy for recurrent or metastatic olfactory neuroblastoma. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1379013"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ejca.2021.03.032","article-title":"Phase II and biomarker study of programmed cell death protein 1 inhibitor nivolumab and metronomic cyclophosphamide in paediatric relapsed\/refractory solid tumours: Arm G of AcSe-ESMART, a trial of the European Innovative Therapies for Children With Cancer Consortium","volume":"150","author":"Pasqualini","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S1470-2045(20)30023-1","article-title":"Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): A multicentre, open-label, single-arm, phase 1-2 trial","volume":"21","author":"Davis","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.2147\/OTT.S124008","article-title":"Targeting the PD-1 pathway in pediatric solid tumors and brain tumors","volume":"10","author":"Wagner","year":"2017","journal-title":"OncoTargets Ther."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e1343775","DOI":"10.1080\/2162402X.2017.1343775","article-title":"PD-1 blockade augments anti-neuroblastoma immune response induced by anti-GD(2) antibody ch14.18\/CHO","volume":"6","author":"Siebert","year":"2017","journal-title":"Oncoimmunology"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Lode, H.N., Ladenstein, R., Troschke-Meurer, S., Struppe, L., Siebert, N., Zumpe, M., Ehlert, K., Huber, S., Glogova, E., and Hundsdoerfer, P. (2023). Effect and Tolerance of N5 and N6 Chemotherapy Cycles in Combination with Dinutuximab Beta in Relapsed High-Risk Neuroblastoma Patients Who Failed at Least One Second-Line Therapy. Cancers, 15.","DOI":"10.3390\/cancers15133364"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1038\/s41467-025-56619-x","article-title":"The anti-GD2 monoclonal antibody naxitamab plus GM-CSF for relapsed or refractory high-risk neuroblastoma: A phase 2 clinical trial","volume":"16","author":"Mora","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Troschke-Meurer, S., Zumpe, M., Mei\u00dfner, L., Siebert, N., Grabarczyk, P., Forkel, H., Maletzki, C., Bekeschus, S., and Lode, H.N. (2023). Chemotherapeutics Used for High-Risk Neuroblastoma Therapy Improve the Efficacy of Anti-GD2 Antibody Dinutuximab Beta in Preclinical Spheroid Models. Cancers, 15.","DOI":"10.3390\/cancers15030904"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"k4226","DOI":"10.1136\/bmj.k4226","article-title":"Comparative safety of immune checkpoint inhibitors in cancer: Systematic review and network meta-analysis","volume":"363","author":"Xu","year":"2018","journal-title":"BMJ"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Lozano, R., Franco, M.E., and Bona, C. (2025). Severe autoimmune hemolytic anemia associated with glucose-6-phosphate dehydrogenase deficiency as a complication of nivolumab treatment: A case report. Int. J. Clin. Pharmacol. Ther., online ahead of print.","DOI":"10.5414\/CP204756"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/11\/1824\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:43:46Z","timestamp":1760031826000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/11\/1824"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,30]]},"references-count":34,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["cancers17111824"],"URL":"https:\/\/doi.org\/10.3390\/cancers17111824","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,30]]}}}